Mersana Therapeutics Net Income
| MRSN Stock | USD 29.08 0.18 0.62% |
As of the 12th of February 2026, Mersana Therapeutics secures the Downside Deviation of 4.14, mean deviation of 7.16, and Risk Adjusted Performance of 0.1165. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mersana Therapeutics, as well as the relationship between them.
Mersana Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.7506 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -62.3 M | -65.4 M | |
| Net Loss | -183.8 M | -174.6 M | |
| Net Loss | -62.3 M | -65.4 M | |
| Net Loss | (16.23) | (17.05) | |
| Net Income Per E B T | 0.91 | 0.81 |
Mersana | Net Income | Build AI portfolio with Mersana Stock |
Evaluating Mersana Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Mersana Therapeutics's fundamental strength.
Latest Mersana Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Mersana Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Mersana Therapeutics financial statement analysis. It represents the amount of money remaining after all of Mersana Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Mersana Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mersana Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (69.19 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Mersana Net Income Regression Statistics
| Arithmetic Mean | (63,192,838) | |
| Coefficient Of Variation | (97.81) | |
| Mean Deviation | 45,937,950 | |
| Median | (38,707,000) | |
| Standard Deviation | 61,810,920 | |
| Sample Variance | 3820.6T | |
| Range | 190.5M | |
| R-Value | (0.63) | |
| Mean Square Error | 2448.2T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (7,734,309) | |
| Total Sum of Squares | 61129.4T |
Mersana Net Income History
Other Fundumenentals of Mersana Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Mersana Therapeutics Net Income component correlations
Mersana Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Mersana Therapeutics is extremely important. It helps to project a fair market value of Mersana Stock properly, considering its historical fundamentals such as Net Income. Since Mersana Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mersana Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mersana Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Search Suggestions
| MR | Montage Resources | CompanyDelisted |
| MRK | Merck Company | Company |
| MRAEX | Meridian Equity Income | Mutual Fund |
| MRAD | Guinness Atkinson Asset | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionMersana Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Mersana Therapeutics reported net income of (69.19 Million). This is 120.27% lower than that of the Biotechnology sector and 198.78% lower than that of the Health Care industry. The net income for all United States stocks is 112.12% higher than that of the company.
Mersana Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mersana Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mersana Therapeutics could also be used in its relative valuation, which is a method of valuing Mersana Therapeutics by comparing valuation metrics of similar companies.Mersana Therapeutics is currently under evaluation in net income category among its peers.
Mersana Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Mersana Therapeutics from analyzing Mersana Therapeutics' financial statements. These drivers represent accounts that assess Mersana Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Mersana Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 439.0M | 548.8M | 269.4M | 175.2M | 201.5M | 191.4M | |
| Enterprise Value | 299.2M | 456.2M | 128.7M | 96.1M | 110.5M | 105.0M |
Mersana Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mersana Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mersana Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Mersana Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Mersana Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Mersana Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mersana Therapeutics' value.| Shares | 683 Capital Management Llc | 2025-03-31 | 1.6 M | Jacobs Levy Equity Management, Inc. | 2025-03-31 | 1.3 M | 5am Venture Management, Llc | 2025-03-31 | 1.3 M | Qube Research & Technologies | 2025-03-31 | 1.2 M | Northern Trust Corp | 2025-03-31 | 864.8 K | Renaissance Technologies Corp | 2025-03-31 | 839.9 K | Deutsche Bank Ag | 2025-03-31 | 839.7 K | Ieq Capital, Llc | 2025-03-31 | 707 K | Lion Point Capital, Lp | 2025-03-31 | 644 K | Nextech Invest, Ltd. | 2025-03-31 | 12.1 M | Bain Capital Life Sciences Investors, Llc | 2025-03-31 | 8.7 M |
Mersana Fundamentals
| Return On Equity | -5.05 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (2.11) % | ||||
| Operating Margin | (0.68) % | ||||
| Current Valuation | 91.27 M | ||||
| Shares Outstanding | 5 M | ||||
| Shares Owned By Insiders | 1.46 % | ||||
| Shares Owned By Institutions | 67.56 % | ||||
| Number Of Shares Shorted | 54.45 K | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 32.03 X | ||||
| Price To Sales | 4.38 X | ||||
| Revenue | 40.5 M | ||||
| Gross Profit | (35.85 M) | ||||
| EBITDA | (63.27 M) | ||||
| Net Income | (69.19 M) | ||||
| Cash And Equivalents | 225.13 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 28.6 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.32 X | ||||
| Book Value Per Share | (11.91) X | ||||
| Cash Flow From Operations | (82.34 M) | ||||
| Short Ratio | 0.79 X | ||||
| Earnings Per Share | (13.95) X | ||||
| Target Price | 30.75 | ||||
| Number Of Employees | 102 | ||||
| Beta | 0.43 | ||||
| Market Capitalization | 145.36 M | ||||
| Total Asset | 144.66 M | ||||
| Retained Earnings | (895.55 M) | ||||
| Working Capital | 74.45 M | ||||
| Current Asset | 71.4 M | ||||
| Current Liabilities | 51.32 M | ||||
| Net Asset | 144.66 M |
About Mersana Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mersana Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mersana Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mersana Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
Moving against Mersana Stock
| 0.94 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.85 | EDIT | Editas Medicine Earnings Call This Week | PairCorr |
| 0.84 | ABP | Abpro Holdings | PairCorr |
| 0.82 | GNLX | Genelux Common | PairCorr |
| 0.78 | IMRN | Immuron Ltd ADR | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could Mersana diversify its offerings? Factors like these will boost the valuation of Mersana Therapeutics. Expected growth trajectory for Mersana significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mersana Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (13.95) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Investors evaluate Mersana Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mersana Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mersana Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Mersana Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mersana Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mersana Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.